NCT06254365Active, not recruiting
Investigating Glucose Metabolism of LEAP2 With Total-body PET/CT
Effects of Antagonizing the Ghrelin Receptor on Total-body Glucose Metabolism in Obesity
Source: ClinicalTrials.gov · Last updated 19 Jun 2025
Brief summary (registry, in English)
The naturally occurring hormone LEAP2 is proposed to have opposite effects to that of the 'hunger hormone' ghrelin. Other that appetite regulation, LEAP2 is involved in glucose metabolism through mechanisms yet not fully understood. With two experimental days; one recieving LEAP2 and one recieving placebo infusion in a randomized order, the study will explore the effect of LEAP2 (vs. placebo) on glucose metabolism through total-body PET/CT-scans and thereby gain a deeper understanding of the ghrelin/LEAP2 system and its interaction with glucose metabolism. Furthermore, the project will generate scanning references in individuals with obesity that are usable in forthcoming research projects.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- First submitted
- 2 Feb 2024
- Start date
- 21 Feb 2024
- Primary completion date
- Sept 2025
- Lead sponsor
- University Hospital, Gentofte, Copenhagen
- Diseases
- Obesity
- NCT number
- NCT06254365
What you commit to
- Study type: Interventional
- Planned participants: 9
- From 21 Feb 2024 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any ongoing medication that the investigator evaluates would interfere with trial participation.
Other illness
- Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥2 times normal values) or present hepatobiliary and/or gastrointestinal disorder(s)
- Any physical or psychological condition that the investigator evaluates would interfere with trial participation including any acute or chronic illnesses
Lab values
- Anaemia (haemoglobin below normal range)
- Nephropathy (serum creatinine above normal range and/or albuminuria)
- Glycated haemoglobin (HbA1c) ≥48 mmol/mol and/or type 2 diabetes requiring medical treatment
Other
- Regular tobacco smoking or use of other nicotine-containing products
- Claustrophobia
Who the study is looking for
- Caucasian
- Age between 18 and 60 years at the time of inclusion
- Body mass index 30-50 kg/m2
- Informed consent
Age in the registry: 18 years to 60 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Clinical Metabolic Research, Gentofte Hospital Coordinator of this site? Confirm its status | Hellerup | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.